Elyxyb (celecoxib) is a brand-name oral solution prescribed for migraine in adults. As with other drugs, Elyxyb can cause side effects, such as changes in your sense of taste and digestive system ...

Shares of Aarti Drugs rose as much as 17.48% to Rs 497.6 apiece, the highest level since November 7. It pared gains to close ...

Aarti Drugs spurted 14.15% to Rs 483.95 after the company received establishment inspection report (EIR) from US Food and Drug Administration (USFDA) for its API manufacturing facility in Tarapur, ...

Neurosense is finalizing the protocol of a Phase 3 study of PrimeC for ALS, and plans to submit the protocol for FDA approval ...

Aarti Drugs share price saw a sudden spike during the final hour of trade on Tuesday, December 24, which made it snap its ...

The study group received a single 400 mg dose of celecoxib, one hour before surgery, and 200 mg of celecoxib every 12 hours for five days, along with patient-controlled analgesic (PCA) morphine.

The labeling for celecoxib, rofecoxib, and valdecoxib was approved by the Food and Drug Administration (FDA) in December 1998, May 1999, and November 2001, respectively. Celecoxib is the only ...

Mumbai: Aarti Drugs Limited has received Establishment Inspection Report (EIR) from the United States Food and Drug ...

The global opioid use disorder treatment market is poised for significant growth, with an expected market size of USD 3.07 ...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for ...

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...

Medically reviewed by William Truswell, MD Hidradenitis suppurativa (HS) is a chronic (long-term) inflammatory skin condition ...